22 hours Ago By Defense World Staff
Renaissance Technologies LLC increased its position in Sanara MedTech Inc. ( NASDAQ:SMTI – Free Report ) by 152.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 35,400 shares of the company’s stock after purchasing an additional 21,400 shares during the period. Renaissance Technologies LLC owned 0.41% of Sanara MedTech worth $1,175,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in SMTI. Wells Fargo & Company MN grew its position in shares of Sanara MedTech by 53.9% in the 4th quarter.
Wells Fargo & Company MN now owns 1,893 shares of the company’s stock worth $63,000 after buying an additional 663 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Sanara MedTech by 127.
2% during the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after purchasing an additional 2,272 shares in the last quarter.
Barclays PLC lifted its holdings in shares of Sanara MedTech by 323.0% during the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after purchasing an additional 4,376 shares during the last quarter.
Bank of New York Mellon Corp boosted its position in shares of Sanara MedTech by 24.0% in the 4th quarter. Bank of New York Mellon Corp now owns 13,054 shares of the company’s stock worth $433,000 after purchasing an additional 2,528 shares in the last quarter.
Finally, Fifth Third Bancorp purchased a new stake in shares of Sanara MedTech in the 4th quarter worth approximately $898,000. Institutional investors own 8.10% of the company’s stock.
Analyst Ratings Changes A number of research analysts have issued reports on SMTI shares. HC Wainwright lifted their price objective on Sanara MedTech from $50.00 to $51.
00 and gave the company a “buy” rating in a research note on Wednesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $46.00 price target on shares of Sanara MedTech in a research note on Wednesday, March 26th.
Sanara MedTech Price Performance Shares of NASDAQ SMTI opened at $32.14 on Wednesday. The firm has a market cap of $285.
66 million, a P/E ratio of -32.46 and a beta of 1.47.
Sanara MedTech Inc. has a twelve month low of $25.86 and a twelve month high of $39.
08. The company has a quick ratio of 2.02, a current ratio of 2.
23 and a debt-to-equity ratio of 0.76. The company has a 50 day moving average of $31.
33 and a 200 day moving average of $33.45. Sanara MedTech ( NASDAQ:SMTI – Get Free Report ) last posted its quarterly earnings results on Tuesday, March 25th.
The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.
01. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.
71%. The firm had revenue of $26.31 million during the quarter, compared to analysts’ expectations of $22.
75 million. As a group, research analysts expect that Sanara MedTech Inc. will post -1.
1 EPS for the current fiscal year. About Sanara MedTech ( Free Report ) Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
See Also Five stocks we like better than Sanara MedTech Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet 3 Fintech Stocks With Good 2021 Prospects Coca-Cola Company Stock Can Bubble to New Highs This Year Insider Selling Explained: Can it Inform Your Investing Choices? 3 Stocks Lifting 2025 Guidance Despite Market Jitters Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter .
.
